OBJECTIVES: To determine economic impact of Procoralan® therapy in stable angina patients as compared to invasive PCI/CABG therapy. METHODS: A cost-minimisation, probabilistic model performed from a third party payer perspective in Poland. Costs calculations were based on the National Health Fund rates. Invasive therapy cost was assumed to be a weighted average of PCI/CABG, according to Poland-specific proportions. Clinical assumptions and risk profiles were derived from the Euro Heart Survey. The economic impact was calculated for the patients not qualified for invasive therapy or maintenance therapy with beta-blocker due to contraindications or intolerance. Both one-way (drug cost) and multi-way (revascularisation risk, reimbursement level) sensitivity analyses were performed. RESULTS: The incremental costs per patient per year were as follows: €747.82-743.34 for Procoralan® 5mg/7.5mg therapy respectively; € 3879.88 for CABG, €2265.88 for PCI. The reduction in payer’s expenditure in the range of €1918.32-1922.81 per patient per year was demonstrated as a result of the application of Procoralan® 5mg/7.5mg therapy instead of the invasive therapy. The obtained result applies to the case of the whole Procoralan® price borne by the payer (100% reimbursement). In the case of 70% and 50% reimbursement rates savings amounted to €2112.09-2115.23 and €2248.05-2250.20 depending on dose of the drug. The sensitivity analyses results showed that change of the Procoralan® treatment cost (+/-50%), wide range of changes in the risk of a secondary revascularisation and the reimbursement level did not influence the ultimate interpretation of the results. CONCLUSIONS: Third party payer’s benefits related to Procoralan® may apply to all patients suffering from angina symptoms having contraindications or intolerance to beta-blocker. The greatest savings concern patients not qualified for invasive therapy as no alternative treatment is effective in this group, but in all scenarios the Procoralan® therapy was proven to be cost-saving for public payer.